Blog

Two datasets. One difference. → Side-by-side comparison of two identical-looking datasets: one labelled "looks clean" but cannot be proven unaltered, the other "provably clean" with every record independently verifiable. What "trustworthy" actually requires → Diagram showing three data-integrity properties — attributable, contemporaneous, and verifiable — all resting on a single assumption: that the audit trail cannot be rewritten by an intruder. The common design: one blast radius → Diagram of a typical single-tier system where one compromised token can reach both the clinical data and the audit trail inside the same trust boundary. Carelane: two tiers, kept apart → Diagram of Carelane's two-tier architecture: a compromised token can reach the application tier but is blocked at a separate trust boundary from the immutable infrastructure logs below.

August 12, 2026

Could you prove your data is untouched after a breach?

Cover image for a Carelane article on how CROs can adopt AI in clinical trials in a compliant, audit-ready way.

How to adopt AI as a CRO

CRO operations infrastructure: fragmented legacy systems versus unified tech-enabled stack for clinical trials.

Becoming a Tech-Enabled CRO

Diagram contrasting two clinical trial operating models. On the left, "Today": the CRO owns the eClinical platform, data, and admin rights, while the biotech sponsor rents access. On the right, "Tomorrow — Bring Your Own CRO": the biotech sponsor owns the platform, data, and infrastructure, while the CRO logs in as a swappable execution partner.

Bring Your Own CRO

The First AI Warning Letter: FDA Doubles Down on Mandatory Human Oversight - Carelane

The First AI Warning Letter: FDA Doubles Down on Mandatory Human Oversight

The Velocity Paradox: Why "Safe" is the New Risky in Clinical Development — Carelane

The Velocity Paradox: Why "Safe" is the New Risky in Clinical Development

Doctor analyzing data and graphs on a laptop at a desk.

August 15, 2025

Carelane sets new standards for clinical research with AI-driven, end-to-end platform

Snow-covered mountain peak under a clear blue sky.

Carelane Raises €800,000 in Pre-Seed Funding to Revolutionize Clinical Trial Software

Three doctors in white coats having a discussion in a modern building with a green world map on the wall.

ECMM has launched the Candida IV study, involving over 100 sites worldwide

Ready to try Carelane?

From protocol to a complete study build in minutes.
Experience the world's fastest infrastructure for modern clinical trials.

Start Your Registry

User interface of Carelane software showing site managemen.

User interface of Carelane software showing Chatbot.

Portrait Yannick Boerner – CEO & co-Founder

Yannick Boerner

CEO & co-Founder